

Subject: Medical Science Liaison (MSL) Notes - Mixed Reactions on PulmoVive

Date: September 5, 2024

Provider: Dr. Melissa Turner

Title: Pulmonologist

Institution: BreatheWell Pulmonary Care Center

Summary of Key Discussion Points:

1. Introduction:

- Introduced PulmoVive as an innovative therapy for COPD management.
- Dr. Turner expressed cautious optimism, acknowledging the need for advancements in COPD treatment.

2. Provider's Current Patient Cases:

- Dr. Turner shared interest in exploring new treatments for patients facing exacerbations.
- Discussed skepticism about the reported efficacy, citing previous disappointments with new COPD therapies.

3. Efficacy and Clinical Data:

- Presented clinical data showing improvements in lung function and reduced exacerbation rates with PulmoVive.
- Dr. Turner acknowledged the promising results but raised concerns about the long-term sustainability of benefits.

4. Safety Profile:

- Discussed the favorable safety profile of PulmoVive, with minimal respiratory adverse events.
- Dr. Turner appreciated the emphasis on safety but expressed reservations about potential unknowns.

5. Mechanism of Action:

- Explained PulmoVive's dual mechanism targeting bronchoconstriction and inflammation.
- Dr. Turner found the dual action intriguing but questioned the necessity for both mechanisms in every patient.

6. Patient Adherence and Education:

- Discussed strategies for enhancing patient adherence through convenient administration.
- Dr. Turner acknowledged the importance of adherence but expressed concerns about patient compliance with new medications.

7. Emerging Research and Future Developments:

- Highlighted ongoing research on PulmoVive's potential in addressing COPD-related comorbidities.
- Dr. Turner expressed interest in further research but emphasized the need for practical, real-world benefits.

8. Competitive Landscape:

- Compared PulmoVive to existing COPD therapies, noting the potential for comprehensive disease management.
- Dr. Turner questioned whether the added benefits justify potential complexities in treatment plans.

9. Access and Reimbursement:

- Provided updates on access and reimbursement programs for pulmonary clinics.
- Dr. Turner appreciated the consideration of access but expressed concerns about potential financial burdens on patients.

10. Action Items and Follow-Up:

- Dr. Turner expressed interest in closely monitoring ongoing studies and real-world evidence.
- Agreed upon a follow-up in three months to discuss emerging data and address any ongoing concerns.

11. Closing Remarks:

- Expressed appreciation for Dr. Turner's thoughtful insights and engagement.
- Reiterated commitment to ongoing collaboration and support for the BreatheWell Pulmonary Care Center.